Valuation: Enliven Therapeutics, Inc.

Market Cap 3.39B 3.01B 2.81B 2.56B 4.82B 326B 4.89B 34.02B 13.17B 166B 12.71B 12.44B 533B P/E 2026 *
-23.8x
P/E 2027 * -20x
Enterprise Value 2.99B 2.65B 2.48B 2.26B 4.26B 288B 4.32B 30.02B 11.62B 147B 11.22B 10.97B 471B EV / Sales 2026 *
-
EV / Sales 2027 * 509,953x
Free-Float
93.78%
Yield 2026 *
-
Yield 2027 * -
1 day+0.81%
1 week+2.30%
Current month+0.81%
1 month-20.13%
3 months-5.23%
6 months+22.28%
Current year+200.06%
1 week 44.19
Extreme 44.19
47.22
1 month 44.18
Extreme 44.175
60.1
Current year 14.78
Extreme 14.785
62.32
1 year 14.78
Extreme 14.785
62.32
3 years 9.8
Extreme 9.8
62.32
5 years 9.8
Extreme 9.8
62.32
10 years 9.8
Extreme 9.8
62.32
Manager TitleAgeSince
Chief Operating Officer 46 2023-02-22
Chief Executive Officer 57 2025-12-10
Chief Tech/Sci/R&D Officer 61 2023-02-22
Director TitleAgeSince
Director/Board Member 63 2023-02-22
Director/Board Member 48 2023-02-22
Director/Board Member 48 2023-02-22
Date Insider Type Main position Quantity % Market Cap. Importance
9/17/26 Exercice

Chief Technology Officer

15,000 0.0205%
9/17/26 Exercice

Chief Financial Officer

13,982 0.0191%
8/17/26 Exercice

Chief Technology Officer

15,000 0.0205%
Change 5-day change 1-year change 3-year change Capi.($)
+0.81%+2.30%+133.09%+238.29% 3.39B
+4.16%+3.04%+49.37%+94.17% 74.41B
-1.00%-1.51%+24.46%+78.24% 59.26B
+1.23%-0.39%+4.54%+34.84% 47.14B
-3.02%-5.20%+27.94%+32.51% 42.91B
+0.31%+3.02%+348.95%+643.82% 44.13B
-1.96%-0.33%+7.04%+99.46% 40.79B
+3.32%+3.49%+10.10%+51.23% 30.77B
-2.68%+2.92%+29.63%+22.72% 29.31B
-4.86%-10.66%-26.27%+330.06% 23.71B
Average -0.38%-0.24%+60.89%+162.54% 39.58B
Weighted average by Cap. +0.04%-0.30%+58.69%+146.60%

Financials

2026 *2027 *
Net sales - 5.56K 4.94K 4.62K 4.21K 7.92K 535K 8.03K 55.87K 21.63K 273K 20.88K 20.42K 876K
Net income -133M -118M -111M -101M -190M -12.82B -192M -1.34B -518M -6.53B -500M -489M -20.98B -175M -155M -145M -132M -249M -16.85B -253M -1.76B -681M -8.58B -657M -643M -27.57B
Net Debt -398M -353M -331M -301M -567M -38.32B -575M -4B -1.55B -19.52B -1.49B -1.46B -62.68B -551M -489M -457M -417M -784M -53B -795M -5.53B -2.14B -26.99B -2.07B -2.02B -86.7B
Logo Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. It is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML). ELVN-001 is an adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitor (TKI). The Company's second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations.
Employees
67
Date Price Change Volume
26-10-01 US$46.21 +0.81% 944,890
26-09-30 US$45.84 -1.44% 800,171
26-09-29 US$46.51 +1.09% 1,256,237
26-09-28 US$46.01 +2.82% 1,284,648
26-09-25 US$44.75 -0.93% 963,790
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
46.21USD
Average target price
74.00USD
Spread / Average Target
+60.14%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ELVN Stock